115 related articles for article (PubMed ID: 24685741)
1. Re: effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Ahmadi F
Iran J Kidney Dis; 2014 Mar; 8(2):158-60. PubMed ID: 24685741
[No Abstract] [Full Text] [Related]
2. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Park JW; Kang SH; Do JY
Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
[TBL] [Abstract][Full Text] [Related]
3. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
[TBL] [Abstract][Full Text] [Related]
4. A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects.
Cappelli G; Amore A; Bandiani G; Cancarini G; Coppo R; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Contrib Nephrol; 2001; (131):97-106. PubMed ID: 11125568
[No Abstract] [Full Text] [Related]
5. Long-term results with low glucose degradation product content in peritoneal dialysis fluids.
Rippe B; Wieslander A; Musi B
Contrib Nephrol; 2003; (140):47-55. PubMed ID: 12800343
[No Abstract] [Full Text] [Related]
6. GDPs and AGEs: local and systemic effects in PD patients.
Ledebo I; Wieslander A; Deppisch R
Contrib Nephrol; 2003; (140):38-46. PubMed ID: 12800342
[No Abstract] [Full Text] [Related]
7. Long-term effect of peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration on peritoneum: a case report.
Shimizu H; Ishibashi Y; Kumagai T; Kaname S; Fujita T; Sai K; Nishi T; Mise N; Tagawa H; Sugimoto T
Perit Dial Int; 2007; 27(1):92-4. PubMed ID: 17179519
[No Abstract] [Full Text] [Related]
8. Glycation and advanced glycation end-product formation with icodextrin and dextrose.
Dawnay AB; Millar DJ
Perit Dial Int; 1997; 17(1):52-8. PubMed ID: 9068023
[TBL] [Abstract][Full Text] [Related]
9. Strategy for preventing peritoneal dialysis failure.
Cancarini G
Contrib Nephrol; 2001; (131):114-24. PubMed ID: 11125557
[No Abstract] [Full Text] [Related]
10. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system.
Passlick-Deetjen J; Lage C
Perit Dial Int; 2000; 20 Suppl 2():S42-7. PubMed ID: 10911642
[No Abstract] [Full Text] [Related]
11. AGE accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function.
Park MS; Lee HB
Perit Dial Int; 1999; 19 Suppl 2():S53-7. PubMed ID: 10406494
[No Abstract] [Full Text] [Related]
12. In vivo model to study the biocompatibility of peritoneal dialysis solutions.
Wieczorowska-Tobis K; Korybalska K; Polubinska A; Radkowski M; Breborowicz A; Oreopoulos DG
Int J Artif Organs; 1997 Dec; 20(12):673-7. PubMed ID: 9506780
[TBL] [Abstract][Full Text] [Related]
13. [Function of the peritoneum in hyperglycemic conditions].
Czyzewska K
Postepy Hig Med Dosw; 1994; 48(3):291-307. PubMed ID: 7971603
[TBL] [Abstract][Full Text] [Related]
14. Long-term peritoneal dialysis-impact of peritoneal membrane changes and newer solutions.
Krediet RT
Int J Artif Organs; 1998 Aug; 21(8):437-9. PubMed ID: 9803343
[No Abstract] [Full Text] [Related]
15. Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs.
Feriani M
Contrib Nephrol; 2001; (131):74-81. PubMed ID: 11125565
[No Abstract] [Full Text] [Related]
16. Glucose degradation products and the peritoneal mesothelium.
Jörres A; Bender TO; Witowski J
Perit Dial Int; 2000; 20 Suppl 5():S19-22. PubMed ID: 11229607
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of transforming growth factor-beta 1 gene overexpression as a strategy to prevent fibrosis.
Gambaro G; Weigert C; Ceol M; Schleicher ED
Contrib Nephrol; 2001; (131):107-13. PubMed ID: 11125556
[No Abstract] [Full Text] [Related]
18. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
19. 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization.
Santamaría B; Ucero AC; Reyero A; Selgas R; Ruiz-Ortega M; Catalán M; Egido J; Ortiz A
Nephrol Dial Transplant; 2008 Oct; 23(10):3307-15. PubMed ID: 18524790
[TBL] [Abstract][Full Text] [Related]
20. Lactate-versus bicarbonate-based peritoneal dialysis solutions.
Pedersen FB
Perit Dial Int; 1995; 15(7 Suppl):S47-50; discussion S51. PubMed ID: 8555326
[No Abstract] [Full Text] [Related]
[Next] [New Search]
